Adalimumab/azathioprine/infliximabMalignant melanoma: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2014年 / 1532卷 / 1期

关键词：

D O I：

10.1007/s40278-014-5827-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：16 / 16

相关论文

共 50 条

[21] Adalimumab/azathioprine/infliximabGlottic oedema and lack of efficacy: case report
Reactions Weekly, 2024, 2035 (1) : 25 - 25
[22] Adalimumab/Azathioprine/MethotrexateAllergic reactions and lack of efficacy: case report
Reactions Weekly, 2024, 2023 (1) : 20 - 20
[23] Adalimumab/azathioprine/immunosuppressantsLiver toxicity and lack of efficacy: case report
Reactions Weekly, 2022, 1912 (1) : 18 - 18
[24] Adalimumab/azathioprine/infliximabHepatosplenic T cell lymphoma: case report
Reactions Weekly, 2009, 1269 (1) : 5 - 5
[25] Adalimumab/azathioprine/methotrexateLack of efficacy and drug intolerance: case report
Reactions Weekly, 2023, 1974 (1) : 18 - 18
[26] Adalimumab/azathioprine/infliximabPulmonary tuberculosis and tuberculosis cutis orificialis: case report
Reactions Weekly, 2018, 1699 (1) : 14 - 14
[27] Adalimumab/azathioprine/ustekinumabAnaphylaxis, genital rash and acquired drug resistance: case report
Reactions Weekly, 2024, 2025 (1) : 23 - 23
[28] Adalimumab/azathioprine/infliximabLymphomas: 2 case reports
Reactions Weekly, 2012, 1391 (1) : 6 - 6
[29] Adalimumab/azathioprine/sulfasalazineMultiple sclerosis like demyelinating lesions and lack of efficacy: case report
Reactions Weekly, 2023, 1959 (1) : 31 - 31
[30] Adalimumab/infliximab/ustekinumabMalignant melanoma, allergic reaction and polyneuropathy: case report
Reactions Weekly, 2023, 1960 (1) : 21 - 21

← 1 2 3 4 5 →